TAIPEI, , May 6, 2016 /PRNewswire/ -- ACT Genomics, an integrated cancer molecular information company that transforms precision cancer care, today announced that the company has raised US$ 12.5 million in Series B funding. Hotung Group, and CDIB Capital Management, led the round with continued participation from existing investors, Eminent II VC, Hua Nan Venture Capital, President International Development and UMC Capital in this round.
Based in Taipei, Taiwan, ACT Genomics is providing comprehensive genomic profiling assays and molecular information to physicians and biopharmaceutical customers. With full spectrum of clinical service, ACT Genomics helps to expand targeted therapy treatment options, predict response to immune-checkpoint inhibitors, and utilize ctDNA based assay to monitor tumor burden and resistant markers, in their CAP-accredited NGS laboratory.
ACT Genomics plans to use the proceeds to further boost the capacity to support the rapid growth and expansion in Japan, Taiwan, Singapore, Malaysia, Thailand, and Hong Kong. The new proceeds will also enable ACT Genomics to ramp up its commercial channels to drive further global expansion, following its move into Asia Pacific region earlier this year.
ACT Genomics Contact:
PJ (Joe) Hsueh, MBA, Chief Operating Officer
Email: pjhsueh@actgenomics.com
Angus Wu, Associate Director, Business Development
Email: anguswu@actgenomics.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/act-genomics-raises-125-million-in-series-b-funding-300263357.html
